On Wednesday, Synaptics, Incorporated (NASDAQ:SYNA)’s shares declined -3.66% to $83.56.
Synaptics, Incorporated (SYNA) declared that Xiaomi, one of the world’s largest mobile manufacturers, has adopted the Synaptics® ClearPad® family of capacitive touchscreen solutions and its family of display driver integrated circuits (DDICs) for its latest smartphones, the Xiaomi Mi Note and Note Pro. By leveraging ClearPad for full in-cell display solutions and DDICs in discrete display implementations, Xiaomi is able to offer customers industry-leading touchscreen performance backed by brighter and sharper Full HD and Wide Quad HD (WQHD) displays.
These latest design wins demonstrate Synaptics’ continued momentum in China and leadership in the broader global mobile market. Xiaomi’s implementations of Synaptics’ solutions is further validation of the strong trend toward touch and display integration being adopted by global OEMs.
Synaptics Incorporated develops, markets, and sells custom-designed human interface solutions for electronic devices and products primarily in China, South Korea, Taiwan, the United States, Japan, and other countries. The company offers its human interface solutions for mobile product applications, counting smartphones, tablets, and touchscreen applications, in addition to mobile, handheld, wireless, and entertainment devices; and other personal computer (PC) product applications, such as peripherals comprising keyboards, mice, and monitors, in addition to remote control devices for desktops, PCs, and digital home applications.
RADA Electronic Ind. Ltd. (NASDAQ:RADA)’s shares gained 4.12% to $2.02.
RADA Electronic Industries (RADA) of Netanya, Israel declared recently that it received an order to produce and supply a tactical air surveillance radar to a leading European defense contractor. The radar will be delivered later this year.
The multi-mission hemispheric radar (MHR) is an S-band, software-defined, Pulse-Doppler, active, electronically scanned array (AESA) radar. It has sophisticated beam-forming capabilities and advanced signal processing, provides multiple missions on each radar platform and offers a unique price point.
The MHR, operating in its RPS-42 aerial surveillance mission, detects and tracks multiple aerial targets, ranging from transport aircraft — through high performing fighter aircraft — down to the smallest multi-copter nano UAVs (unmanned aerial vehicles). As a result, several customers have selected the RPS-42 for aerial surveillance missions.
RADA Electronic Industries Ltd. engages in the development, manufacture, and sale of defense electronics to various air forces and companies worldwide. The company offers military avionics systems, counting flight data recorders for fighter aircraft; digital video/audio/data recorders with data transfer functions; high-rate data recorders for aircraft and airborne pods; video recorders and airborne data servers; a range of head-up-displays color video cameras for fighter aircraft; and various ground debriefing solutions.
At the end of Wednesday’s trade, Sabre Corp (NASDAQ:SABR)‘s shares surged 1.76% to $24.22.
Sabre Corporation (SABR) declared that it has designated Roshan Mendis as senior vice president for Sabre Travel Network, Asia Pacific, following the completion of its acquisition of Abacus International recently.
In his new role, Mendis will be responsible for the overall Sabre Travel Network business in the Asia Pacific region which will comprise the newly attained Abacus business.
Mendis joins the team following 12 years with Travelocity.com, where he was most recently president of the Americas, until its sale in early 2015 to Expedia. Mendis was also formally president of Zuji, Travelocity’s Asia Pacific brand, based in Singapore, and prior to that, vice president of Travelocity Partner Network.
Sabre Corporation provides technology solutions to the travel and tourism industry worldwide. It operates in two segments: Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, counting airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators, with a network of travel buyers comprising online and offline travel agencies, travel administration companies, and corporate travel departments. The Airline Hospitality Solutions segment offers a portfolio of software technology products and solutions through software-as-a-service and hosted delivery models to airlines, hotel properties, and other travel suppliers.
Sarepta Therapeutics Inc (NASDAQ:SRPT), ended its Wednesday’s trading session with -2.23% loss, and closed at $29.75.
Sarepta Therapeutics Inc (SRPT) a developer of innovative RNA-targeted therapeutics, granted an equity award recently to Rachel Chan. The award was formerly approved by the Compensation Committee of Sarepta’s Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to Ms. Chan’s employment as a Chemistry Lab Aide at Sarepta in May 2015. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4).
Ms. Chan received an option to purchase 600 shares of Sarepta’s common stock. The option has an exercise price of $25.62 per share, which is equal to the closing price of Sarepta’s common stock on May 29, 2015. One-fourth of the shares underlying Ms. Chan’s option will vest on the one year anniversary of her date of hire and thereafter 1/48th of the shares underlying Ms. Chan’s option will vest monthly, such that the shares underlying the option will be fully vested on the fourth anniversary of her date of hire, subject to her continued employment with Sarepta on each such vesting date.
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
